The 2026 biopharmaceutical M&A and VC outlook shows a rebound in deal activity driven by renewed M&A, more flexible deal structures, and shifting venture investment patterns—trends also reflected in the licensing and transaction data tracked by DealForma. Read it here
DealForma is the biopharma deal database providing you comprehensive information and dedicated analyst support to help you be more confident using quality data in your business development research.
Database
Company
Comparisons
Website Design by Once Interactive
